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ABSTRACT 
Klebsiella pneumoniae and Escherichia coli are pathogens belonging to the 
Enterobacteriaceae family. They can cause infections ranging from uncomplicated urinary 
tract infection to severe bloodstream infection (BSI). The prevalence of extended spectrum β-
lactamase-producing Enterobacteriaceae (EPE) is increasing worldwide and carbapenemases 
(CPE), a subgroup of EPE where antibiotic treatment is very limited, is a major threat to 
patients.The aims of this thesis were to get expanded molecular and epidemiological 
knowledge about K. pneumoniae, its association to morbidity and mortality in BSI (II, III), to 
increase sensitivity in detection of carbapenemase-producers (I), to determine risk to acquire 
fecal colonization with EPE during traveling, and to characterize colonizing EPE in terms of 
virulence factors and phylogroups (IV). 
                In paper I methods for antimicrobial susceptibility testing were evaluated for 
detection of K. pneumoniae carbapenemase (KPC)- and Verona integron-encoded metallo--
lactamase (VIM)-producing K. pneumoniae in order to define appropriate screening 
breakpoints. Strains (n=51) were tested against different carbapenems using disk diffusion, 
gradient test, and automated susceptibility testing. Results were interpreted with the European 
(EUCAST) and American (CLSI) antimicrobial susceptibility testing breakpoints. We found 
that clinical breakpoints cannot be used for carbapenemase screening. Meropenem was the 
most suited carbapenem to use for screening purposes. A breakpoint of 0.5 mg/L detected all 
isolates with an at the same time good separation from the wild type population. 
              In paper II and III a cohort of patients with BSI caused by K. pneumoniae was 
evaluated retrospectively and compared with BSI caused by E. coli. Data on risk factors, 
prognostic factors and mortality was retrieved from 1251 medical charts (III). The late 
mortality (within 90 days) was significantly higher among patients with BSI caused by K. 
pneumoniae and could be explained by higher comorbidity. Contrary to European trends our 
study showed low antibiotic resistance among K. pneumoniae isolates supporting the 
hypothesis of absence of successful multidrug-resistant K. pneumoniae clones in the 
Stockholm area. For a subset of the patients (n=139) molecular analysis was performed on 
the K. pneumoniae isolates (II). Based on multilocus sequence typing, the isolates could be 
separated in three phylogenetic clades: KpI (n=96), KpII (n=9) and KpIII, also known as K. 
variicola (n=34). Patients infected with strains belonging to K. variicola had higher 30 days 
mortality (29.4 %), also when adjusting for age and comorbidity (OR for KpIII = 3.0 (95% 
CI: 1.1-8.4) compared to KpI). Only three of the isolates causing mortality within 30 days 
belonged to any of the virulent serotypes, had a mucoid phenotype, or harbored virulence 
genes. Hence, the increased mortality could not be related to any known strain factor. In 
general, a high level of comorbidity was observed in the K. pneumoniae cohort. 
              Paper IV was a prospective study. Fecal samples and survey data were collected 
from 188 Swedes traveling to four regions of high EPE prevalence, and molecular 
characterization was performed on EPE. Colonization incidence varied by visited region; the 
Indian subcontinent 49%, northern Africa 44%, Southeast Asia 19% and Turkey 10%. Few 
strains harbored virulence factors connected to uropathogenicity, and most E. coli strains 
belonged to phylogroup A, rarely associated with extraintestinal infections. No clinical 
infections were seen in follow-up. No CPE was found, but one strain contained the plasmid-
mediated colistin resistance gene, mcr-1. Independent risk factors for EPE acquisition were 
travelers´ diarrhea and use of antibiotics during travel. EPE acquired during travel have 
seemingly low pathogenicity as indicated by the low frequency of virulence factors and 
phylogroups associated with extraintestinal infections. 
 
In summary this thesis provides new knowledge about K. pneumoniae BSI in a clinical and a 
molecular perspective. It also adds to the knowledge about molecular features of EPE 
colonizing the intestine, and appropriate breakpoints to use in detection of CPE. 
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1 INTRODUCTION 
Extended spectrum β-lactamase (ESBL) -production among bacteria belonging to the gram-
negative family Enterobacteriaceae is the clinically most significant mechanism causing 
antibiotic resistance among gram-negatives and is rapidly increasing worldwide. 
Enterobacteriaceae is a large bacterial family comprising several species. Apart from being 
colonizers of the gut microbiota of both animals and humans and being found in water and 
soil, some of the members also serve as human pathogens. Infections range from urinary tract 
infection (UTI), abdominal infection and pneumonia to severe bloodstream infection (BSI) 
[1]. The pathogens focused on in this thesis are two most common pathogens in the 
Enterobacteriaceae family - Escherichia coli and Klebsiella pneumoniae. In most geographic 
regions K. pneumoniae is the pathogen with the highest rate of ESBL-associated resistance 
[2]. 
ESBL-producing Enterobacteriaceae (EPE) most often cause infections of similar severity as 
non-EPE. However, patients with infections caused by EPE are subjected to longer 
hospitalization and more frequently suffer from complications due to delayed adequate 
antibiotic treatment. Infections caused by EPE are also associated with higher costs [3-5]. In 
Sweden the proportion of EPE among E. coli and K. pneumoniae is, compared to many other 
countries, still relatively low. In 2014 the Public Health Agency in Sweden published a study 
on intestinal EPE-colonization among healthy Swedes. The prevalence was 4.8% for samples 
collected 2012-2013 [6]. However resistance rates are higher in hospital settings and increase 
in a manner that at this date causes clinical challenges on an everyday basis. At Karolinska 
University Hospital in Stockholm, the rate of ESBL-producers among invasive E. coli 
isolates was 4 percent in 2006. In 2014 the rate for the first time exceeded 10% [7]. 
β-lactam antibiotics are a broad class of antibiotics including the penicillins, cephalosporins, 
monobactams and carbapenems. The group is important and forms the basis of antibiotic 
treatment of severe infections caused by both gram-negative and gram-positive bacteria. 
Common to all β-lactams is the molecular ring-shaped structure, the β-lactam ring, forming 
the mode of action by binding to penicillin-binding proteins in the bacterial cell wall thus 
inhibiting cell wall synthesis (Fig. 1) [1].  
 
Figure 1. Structural features of a carbapenem with the β-lactam ring (red) 
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Antibiotic resistance among Enterobacteriaceae can occur by several mechanisms (Fig. 2). 
Efflux pumps in the bacterial cell wall reduce the bacterial accumulation of antibiotics. Due 
to loss of porins in the outer bacterial membrane, permeability decreases preventing antibiotic 
influx. However, the most important mechanism is antibiotic degrading enzymes, ESBLs. 
ESBLs are a group of diverse, mostly plasmid-mediated enzymes that can be produced by all 
Enterobacteriaceae. The most common and clinically most important species are E. coli and 
K. pneumoniae. Through hydrolysis the enzymes cause an opening of the β-lactam ring of 
penicillins, cephalosporins and monobactams, which in turn leads to an inactive form of the 
β-lactam antibiotic [2].  
 
 
 
 
 
 
 
Figure 2. Mechanisms of antibiotic resistance in Enterobacteriaceae. 
The bacterial cell wall consists of an outer and an inner membrane surrounding the 
periplasmic space. 
A. Decreased permeability due to loss of porins 
B. Reduced antibiotic accumulation due to active efflux pumps 
C. Plasmid-mediated enzyme production inactivating β-lactams through hydrolysis 
 
Co-resistance to other important antibiotic classes such as fluoroquinolones, trimethoprim-
sulfamethoxazole and aminoglycosides is common among EPE challenging antibiotic 
treatment even more. In severe infections caused by EPE the drugs of choice are the 
carbapenems [8, 9], a group of β-lactam antibiotics that resist inactivation from classical 
ESBLs. 
B. C. A.  
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The major worldwide threat is carbapenemase producing Enterobacteriaceae (CPE), EPE 
resistant also to carbapenems. Severe infections caused by CPE have high mortality due to 
very few, if any, treatment options, and the increasing rate of their occurrence is very 
worrisome.  
K. pneumoniae is second to E. coli the most common gram-negative pathogen causing BSI 
and UTI. The pathogen disseminate more easily than E. coli in hospitals probably due to 
circulating clones hosting specific virulence factors (VFs) [10-12]. The patient population 
affected by invasive infections caused by K. pneumoniae show high comorbidity - diabetes, 
immunosuppression, malignancies and hospitalization are risk factors for BSI caused by K. 
pneumoniae. Invasive infections caused by this pathogen are associated with high mortality 
both in settings with high and low antibiotic resistance rates [13-15]. Most recent studies on 
K. pneumoniae focus, due to the escalating proportion of resistance, on β-lactamase 
producing isolates. 
Taxonomic studies on K. pneumoniae have led to splitting of the species into three distinct 
species. Isolates belonging to phylogroup KpI are now called K. pneumoniae sensu stricto, 
KpII K. quasipneumoniae, and KpIII K. variicola [16, 17]. The knowledge on differences in 
disease presentation and prognosis in infections caused by the different species is limited due 
to the novel change of classification and its limited impact on clinical practice thus far. 
Antimicrobial resistance among bacteria can be traced several thousand years back and the 
bacterial inherent ability to adapt to environmental changes and express resistance genes is 
incredible [18-20]. High use of antibiotics select for resistant strains by suppressing the 
commensal microbiota and creating a niche for resistant strains to breed. Chromosomally 
mediated antibiotic resistance occurs by spontaneous mutations in the bacterial genome that 
are vertically inherited when bacteria divide. The success of EPE has several aspects. One 
important factor is that genes coding for ESBL not only are inherited on bacterial division, 
but also are transferable between bacteria horizontally through plasmids [21]. The mechanism 
is called bacterial conjugation and is further explained in Fig. 3. 
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Figure 3. Schematic illustration of antibiotic resistance selection and bacterial conjugation. 
Susceptible intestinal bacteria (blue) are suppressed due to antibiotic exposure, favoring 
resistant bacteria (red) to breed. A pilus (not shown in figure) hooks to join the donor and 
recipient bacterium. In turn the plasmid, carrying genes encoding for virulence and antibiotic 
resistance, replicate independently and transfer to susceptible bacteria causing horizontal 
antibiotic resistance transfer. 
Another factor contributing to the increasing proportion of EPE is the resistant strains´ 
adaptation as environmental habitants as well as pathogens. High levels of antimicrobial 
resistance, for example metallo-β-lactamase-production in Salmonella Typhimurium [22], is 
associated with bacterial fitness reduction in terms of decreased growth rate and loss of 
invasiveness. However, some successful clones of resistant Enterobacteriaceae show both 
good adaptations as part of the commensal microbiota, as well as low fitness cost. The 
mechanisms are not yet fully understood. One example is the E. coli clonal group, sequence 
type 131 (ST131), commonly reported to harbor bla CTX-M-15, and other co-resistance genes. 
ST131 is a common intestinal colonizer, but also a frequent uro- and bloodstream pathogen 
and a strain known for worldwide dissemination. It belongs to phylogroup B2, a phylogroup 
often associated with extraintestinal infections [23-25]. Some β-lactamase producing K. 
pneumoniae strains have been suggested to possess even higher pathogenic potential than 
non-producers due to simultaneous expression of plasmid encoded adhesins, VFs facilitating 
bacterial adherence to host surfaces [26, 27].  
The dissemination of EPE around the world has been shown both in prevalence studies and in 
studies following travelers to endemic areas [28, 29]. Intestinal colonization with EPE is 
common in many parts of the world, and the duration of fecal carriage varies - colonization 
seem to persist longer following a clinical infection and among newborn than among healthy 
individuals without clinical symptoms [30-32]. However, the future risk of developing a 
clinical infection caused by EPE when colonized is not yet well known. 
 
plasmid 
chromosome 
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The overall aim of this thesis was to study the bacterium K. pneumoniae from different 
aspects – risk factors for and prognosis in severe infections in comparison with E. coli, 
bacterial characteristics in terms of virulence and phylogroups in relation to prognosis, 
diagnostics for multi-resistant isolates, and finally evaluate risk factors for EPE acquisition 
and molecular features of EPE in intestinal colonization. 
More specifically the aims of the studies presented in papers I-IV were: 
 
1. To determine screening breakpoints for laboratory detection of K. pneumoniae 
producing ESBLCARBA (I) 
2. To determine phylogroups and virulence characteristics in K. pneumoniae causing 
BSI in the Stockholm area (II) 
3. To evaluate differences in prognosis in K. pnuemoniae BSI in relation to molecular 
characteristics (II) 
4. To define risk factors for and prognosis in BSI caused by K. pneumoniae in relation to 
Escherichia coli (II, III) in a low resistance setting 
5. To study how relative frequencies of BSI caused by K. pneumoniae versus E. coli 
vary with the frequency of ESBL-producing isolates in those species (III) 
6. To study risk factors for acquisition of EPE when traveling in high-prevalence areas 
(IV) 
7. To study molecular characteristics of EPE colonizing the intestine (IV) 
 
In this thesis frame I will give an introduction to the commensal gut microbiota, its 
importance, and changes in composition due to antibiotic pressure. I will then focus on the 
pathogens of importance, and their molecular characteristics, followed by an introduction to 
the worrying dissemination of EPE and CPE. Lastly I will discuss tools used in the 
diagnostics of carbapenemase-producers, treatment of CPE, and future aspects of multidrug-
resistance (MDR). The findings in the four papers included in this thesis will be integrated 
within each section. The methods used in the studies are fully described separately in the 
papers for which reason they are only partly repeated here to facilitate the understanding.  
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2 THE INTESTINE – THE BODY´S LARGEST BACTERIAL 
RESERVOIR 
The community of microbes living in association with its host is called the microbiome or the 
commensal microbiota. The intestine contains the main proportion of the commensal 
microbiota. It is a fascinating ecosystem consisting of 1-2 kg of at least 1000 different 
bacterial species. The bacterial number has for a long time been estimated to 10:1 (10
13
 
bacteria or 10
11–1012/g) compared to number of cells in the body, although this ratio has 
recently been questioned [33][34]. The bacterial establishment starts during the birth process 
when the child on the way through the birth canal is colonized by the mother’s vaginal- and 
intestinal microbiota. E. coli is one of the first bacterial species to colonize the gut during 
infancy, reaching high density before the anaerobes establish. After the age of two the 
intestinal composition has stabilized and now, depending on the intestinal conditions, more 
than 99 % of the bacteria are anaerobic [35]. Of the facultative bacteria, E. coli still is the 
most common, but is now outnumbered by the anaerobic bacteria by between 100:1 to 
10000:1 [36]. The intestinal ecosystem in adults is diverse and complex and the relative 
abundance (RA) of different species is constantly changing due to interaction with present 
bacteria, nutrition and other host factors such as age, lifestyle factors and diet [37]. As 
bacterial transmission from mother to newborn occurs at birth, EPE colonization of the 
mother is a risk factor for colonization also of the newborn [38, 39]. In a study from India 
carrier rates of EPE were 14.3% day one, and as high as 41.5% day 60, among vaginally 
delivered babies [40].  
2.1 THE NORMAL GUT MICROBIOTA – FUNCTION AND IMPORTANCE 
The full complexity of the microbiota is only in the beginning of being understood and 
currently intensively explored [41]. It contributes with several beneficial functions for the 
host. Colonization resistance serves as a key defense both against exogenously introduced 
gastrointestinal infectious pathogens as well as overgrowth of potential pathogens [42, 43]. 
The mechanisms of action are both direct and indirect (immune-mediated). By occupying the 
colonization niche the commensal microbiota prevents access to mucosal adherence sites and 
inhibits colonization of exogenous pathogens, such as Salmonella Typhimurum and Vibrio 
cholerae or certain strains of pathogenic E. coli. It also prevents overgrowth of indigenous 
potential pathogens such as Clostridium difficile and yeasts. Indirectly commensal bacteria 
and their products can activate the host’s immune response targeting pathogenic bacteria [44]. 
The specific bacteria of most importance in this defense are not yet fully understood but seem 
to constitute the majority of the intestinal microbiota including the two dominating 
commensal bacterial phyla, the Bacteroidetes (including the anaerobic Bacteroides spp) and 
the Firmicutes (including the Lactobacillus spp), and also the Actinobacteria (including 
Bifidobacterium spp) [44].  
Enzymes produced by the microbiota also facilitate digestion of complex carbohydrates and 
generates essential nutritional factors, including vitamins [45]. Recently several diseases – 
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particularly autoimmune - such as type 2 diabetes and inflammatory bowel disease, but also 
obesity and even neuropsychiatric disorders have been found to be linked to imbalance in the 
gut microbiota [46-48]. The RA of some members of the intestinal microbiota depend more 
on host genetics, while others, e.g. the Bacteroides spp, are more influenced by 
environmental factors, for example food and intake of antibiotics [49].  
2.1.1 Escherichia coli 
E. coli are gram-negative, non-sporulating, motile, fermenting, rod-shaped bacteria, with an 
enormous diversity within the species. Most E. coli strains have low pathogenicity and 
belong to the commensal microbiota where they are the most frequent facultative anaerobes 
in the mucus layer of the colon, with a quantity of 10
7
-10
9
 cfu/gram of feces [36]. It is not 
entirely known why E. coli is such a successful competitor in the colon, however, better 
utilization of available nutrients than other species is speculated [50]. Apart from being a gut-
colonizer, E. coli is also the most important gram-negative pathogen causing infections 
ranging from lower to upper UTI, abdominal infection, pneumonia, BSI and meningitis. 
Certain strains can also cause intestinal infections [51]. 
The barrier that separates commensialism from infection is a complex balance between host 
and bacteria. Studies on E. coli have revealed that bacterial behaviour differ between 
phylogroups why attempts to link phylogenetic background with other bacterial traits have 
been made. E. coli can be divided into four major phylogroups; A, B1, B2 and D. Nowadays, 
using a quadruple PCR, totally eight E. coli phylogroups are known; in addition to the major 
ones also C, E, F and Escherichia cryptic clade I [52]. Commensal strains mostly belong to 
group A and B1 while phylogroup B2 and, to some extent, D, are connected to longer 
duration of intestinal colonization, more virulent strains, and are more often causing extra-
intestinal infections (ExPEC) [53-55]. E. coli strains belonging to a non-B2 phylogroup to a 
greater extent show multiresistance, i.e. non-susceptibility to 3 or more different antibiotic 
classes. The reason is unknown but one hypothesis is that commensal strains, commonly non-
B2, become more intestinally exposed to antibiotics [56, 57].  
By multilocus sequence typing (MLST), analyzing DNA-sequences in 7 different 
housekeeping genes, sequence types (STs) can be determined [58] in order to characterize 
genetic relationships among bacterial isolates. International databases store information on 
registered STs, at present almost 5900 different ST:s are registered in the MLST database 
(http://mlst.ucc.ie). 
Several VFs are of importance for E. coli. VFs help bacterial attachment to host mucosal 
surfaces, stimulate inflammation and help the pathogen to overcome immunologic respons. 
Some virulence genes have been correlated to successful intestinal colonization in human, i.e. 
certain traits classically regarded as VFs may also be colonization factors [51]. The main VFs 
associated with ExPEC include adhesins, (e.g. pap - pili associated with pyelonephritis - 
encoded P-fimbriae and fimH- encoded type 1 fimbriae), toxins (hemolysin), iron acquisition 
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systems (aerobactin, siderophore), capsule production (K1/K2/K5) and protectins (colicin) 
[59, 60]. 
2.1.2 Klebsiella pneumoniae 
Klebsiella spp is also a genus of gram-negative, non-sporulating, fermenting, facultative 
anaerobic, rod-shaped bacteria. They are nonmotile. Like E. coli, K. pneumoniae have a high 
degree of plasticity, with gene loss or gain of genomic segments by lateral gene transfer. The 
bacteria can thrive in a variety of environmental niches due to metabolic versatility. Apart 
from being colonizers of mucosal surfaces (i.e. intestine, upper respiratory tract) both in 
human and other mammals, the bacteria can be found both in water, plants, insects and soil 
[61]. Colonization rates vary with increasing rates among hospitalized patients and with 
consumption of antibiotics [62, 63].The bacteria also constitute importance as pathogens 
causing clinical infections such as UTI, pneumonia, abdominal infection, BSI and meningitis, 
often in immunocompromised patients [64]. In some parts of the world, particularly 
Southeast Asia, K. pneumoniae is a cause of pyogenic liver abscess among previously healthy 
individuals [65-67]. There are several species within the genus, of which the clinically most 
important is K. pneumoniae.  
By genotypic methods K. pneumoniae sensu latu can be divided into three different 
phylogroups; KpI, KpII and KpIII. Taxonomic work has proposed the names K. variicola, for 
phylogroup KpIII and K. quasipneumoniae for phylogroup KpII [16, 17]. This phylogenetic 
separation into three different species is novel and yet little is known about differences in 
pathogenesis and virulence. In turn, K. pneumoniae comprises three subspecies: K. 
pneumoniae subsp. pneumoniae, K. pneumoniae subsp. ozaenae and K. pneumoniae subsp. 
rhinoscleromatis. The two latter subspecies are rarely encountered and are associated with 
specific diseases (rhinoscleroma and ozena, respectively) [68]. K. quasipneumoniae also 
includes two subspecies (Fig. 4). 
 
 
Figure 4. K. pneumoniae in a taxonomical perspective 
The bacterial capsule is considered an important VF, 78 different capsular (K antigen) 
serotypes are known [64, 69]. It is composed of polysaccharides forming thick bundles of 
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fibrillous structures covering the bacteria thus protecting it from macrophage-mediated 
phagocytosis and bactericidal serum factors. Different K antigens have been associated with 
invasive disease (K1, K2, K5, K20, K54 and K57) [70, 71] as well as pyogenic liver abscess 
(K1, K2) [72, 73]. Lipopolysaccharide (LPS) protects from complement-mediated killing 
activity and mediate adhesion to uroepithelial cells in vitro [74, 75]. Strains of K. pneumoniae 
forming hypermucoviscous colonies (Fig.5), often serotype K1 and K2, are associated with 
virulence due to the extra layer of polysaccharide, and rmpA (regulator of the mucoid 
phenotype) and magA (mucoviscosity associated gene A) are genes encoding factors 
connected to hyper-virulent K. pneumoniae [76-78]. Other VFs include adherence factors 
(pili, type 1 fimbriae and other adhesins) facilitating host mucosa adhesion, and siderophore 
(enterochelin, aerobactin) activity [64]. 
 
 
 
Figure 5. K. pneumoniae, hypermucoviscous phenotype, forming viscous strings larger than 
5 mm in length when pulling with inoculation loop. 
 
As for E. coli, sequence types (STs) can be determined with MLST. At present over 2000 
different STs are registered in the Klebsiella Sequence Typing database 
(http://bigsdb.web.pasteur.fr/klebsiella/). Isolates differing in only one allele in MLST form a 
clonal complex. Examples of successful sequence types are ST258, a KPC-producer, which 
rapidly have disseminated worldwide, and ST15 and ST147, often hosting CTX-M-15 [11, 
24, 79, 80]. 
2.1.2.1 Klebsiella pneumoniae sensu stricto 
K. pneumoniae is clinically the most significant of the Klebsiella spp, causing a wide range of 
infections. It is second to E. coli the most frequent gram-negative pathogen. 
2.1.2.2 Klebsiella variicola 
The bacterium was for the first time in 2004 described as a separate Klebsiella-genus difficult 
to distinguish from K. pneumoniae by biochemical tests but more reliably differentiated by 
genotypic methods. [16, 81] It has frequently been isolated from various plants, and in a few 
studies also been described from clinical samples causing infections among human. Since 
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around 20% of clinical isolates of K. pneumoniae sensu latu in fact are either K. variicola or 
K. quasipneumoniae, the clinical impact of these pathogens is not yet well known [81].  
2.1.2.3 Klebsiella quasipneumoniae 
The pathogen has recently been described as a novel species closely related to K. pneumoniae 
[17]. It has been isolated from persons with hospital-acquired infections or gut colonization, 
but there are also a few case reports describing liver abscess and a hypermucoviscous isolate 
of K. quasipneumoniae causing BSI [82, 83]. 
2.2 ANTIBIOTICS AND IMPACT ON THE INTESTINAL ECOSYSTEM 
Antibiotics change gut microbiota composition by suppressing species sensitive to the 
specific antibiotic. By killing commensal micro-organisms, both direct bacterial inhibition 
and microbiota-mediated innate immune defenses decrease enabling remaining, antibiotic-
resistant, species to proliferate. When anaerobic bacteria, such as the beneficial Bacteroides 
spp, are suppressed, Clostridium difficile, a species commonly isolated in low numbers in 
healthy individuals, can increase and cause clinical symptoms ranging from mild diarrhea to 
pseudomembranous colitis [84, 85]. Substantial relative changes in microbial abundances are 
seen on exposure to antimicrobials, changes are inter individual and are seen up to several 
months after termination of antibiotic treatment [86]. Apart from selecting for more resistant 
and non-beneficial microbes, the use of antibiotics has also been suggested to be correlated to 
alterations in glucose metabolism, bodyweight regulation and as a consequence development 
of diabetes type 2 [87, 88]. Thus in several ways antibiotic treatment, when indication is 
lacking, can be of harm both on an individual basis and in a global perspective. 
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3 INVASIVE INFECTIONS CAUSED BY K. PNEUMONIAE 
AND E. COLI 
3.1 COLONIZATION VERSUS INFECTION 
Gram-negative infections in the urinary tract and invasive infections are often preceded by 
intestinal colonization and/or colonization of the vaginal introitus and the periurethral area. 
All mammals are colonized with E. coli. Colonization per se is not harmful, but strains 
expressing VFs can easier invade the urinary tract and other host mucosa and cause infection. 
UTIs caused by E. coli are common, with an annual incidence as high as 10-14% among 
sexually active women [89, 90]. E. coli is also the most common species in gram-negative 
invasive infections, a population-based Canadian study showed an annual incidence of 
30/100 000 [91].   
K. pneumoniae is in a healthy individual most often outcompeted by other species in the 
microbiota. However colonization rates vary depending on environmental factors and 
antibiotic pressure. Patients in intensive care units (ICU) show high colonization rates both in 
the stool and in the respiratory tract, increasing the risk for future infections [62-64]. 
The pathogenic potential among Enterobacteriaceae is variable between and within the 
bacterial species. Bacteria capable of causing infections in healthy individuals are more 
dependent on VFs for attachment to the infecting site, to facilitate invasion, and to overcome 
the host’s immune-system, than opportunistic pathogens in immunocompromised hosts [92]. 
With increasing resistance rates in Enterobacteriaceae the prevalence of EPE-carriers 
increase. EPE-colonization in patients with chemotherapy induced neutropenia as well as in 
patients at the ICU pose an increased risk for BSI caused by EPE compared non-carriers [93-
95]. Both patient groups are vulnerable with lacking functional endogenous barriers, hence 
presence of VFs is of less importance for the bacteria to overcome host defenses and cause 
infection. Also, these patients are to a higher extent colonized by more virulent strains and 
species due to high antibiotic pressure. However, the risk among healthy asymptomatic EPE-
carriers to develop invasive infections due to the colonizing strains is not yet well known. In a 
retrospective study by Rottier et al [96] prior colonization with EPE had a positive predictive 
value for the risk of a suspected gram-negative BSI to be caused by EPE of 7.5%. 
3.2 CLINICAL CHARACTERISTICS 
In total 652 adult patients were admitted to Karolinska University Hospital between 2006 and 
2012 due to BSI caused by K. pneumoniae. To determine risk factors for, and prognosis in, 
invasive infection caused by K. pneumoniae we retrospectively reviewed this cohort of 
patients (paper II and III). Patients with bacteria in the cerebrospinal fluid were also 
included, and the terms invasive infection and BSI are here used synonymously.  
To evaluate differences in invasive infections caused by K. pneumoniae and E. coli, patients 
not co-infected with E. coli (n=599) were in paper III matched 1:1 on sex, age and year of 
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disease, with patients having invasive infection caused by E. coli. Data on clinical 
characteristics were retrieved from the medical charts.  
The median age was 68 years, and 58% of the patients were male. Patients with invasive 
infections caused by K. pneumoniae showed in general a higher level of comorbidity (higher 
Charlson index) than the E. coli cohort. The independent risk factors for invasive infection 
caused by K. pneumoniae as compared to E. coli are presented in table 1. 
Table 1. Clinical characteristics of patients with invasive infection caused by K. pneumoniae 
versus E. coli. Factors significant in multivariable analysis (III), using conditional logistic 
regression, are displayed. 
 
Patients factors Adjusted odds ratio  
(95% CI) 
K. pneumoniae vs E. coli 
Arrhythmia 0.64 (0.41-1.00) 
Peripheral vascular disease 4.37 (1.89-10.10) 
COPD 2.01 (1.18-3.45) 
Kidney disease 2.00 (1.34-2.98) 
Bile disease 3.31 (1.57-6.98) 
Hematological malignancy 1.91 (1.16-3.15) 
Colorectal malignancy 3.09 (1.57-6.11) 
Bile/liver/pancreas malignancy 3.34 (1.73-6.46) 
Urinary catheter 2.50 (1.73-3.61) 
Central catheter 2.29 (1.49-3.53) 
Hospital-acquired infection
 a)
 0.54 (0.38-0.78) 
Healthcare- associated community-onset
a)
 3.14 (2.07-4.76) 
 
a) in relation to community-acquired infection 
 
 
In concordance with previous studies, patients with an impaired host defense due to either 
immunocompromising comorbidity, or to indwelling catheters disrupting mucosal 
membranes, are at risk for invasive infections caused by K. pneumoniae [97, 98], also in 
comparison with E. coli. Malignancy was the most common comorbidity in the K. 
pneumoniae cohort; 318 patients (53%) versus 226 (38%) in the E. coli cohort (p<0.001). The 
7-day and 30-day mortality showed no differences between the cohorts, 6 % versus 7%, 
p=0.55, and 15% versus 12%, p=0.15 respectively. Higher 90-day mortality was observed in 
the K. pneumoniae cohort, 26%, versus the E. coli cohort, 17% (p<0.001). Multivariable 
analysis revealed that the difference could be attributed to higher comorbidity (i.e. 
malignancies and severe liver disease), non-community acquired infections, more often 
polymicrobial infections and other source of infections than the urinary tract (III). 
Prognostic factors were evaluated among all K. pneumoniae BSI episodes (n=652). High age, 
lung malignancy and infections emanating from the lungs were factors associated with both 
early (within seven days) and late (up to 90 days) mortality. As expected, polymicrobial 
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infections were associated with fatal outcome within 7 days, while high level of comorbidity 
(i.e. high Charlson index) and other host factors were of major importance for fatal outcome 
within 90 days. 
3.3 BACTERIAL CHARACTERISTICS 
In addition to retrieving clinical information from the medical charts, the isolates from the 
patients admitted to Karolinska University Hospital Solna with BSI caused by K. pneumoniae 
2007-2009 (n=139), were in paper II investigated with molecular methods to look for links 
between bacterial characteristics, and prognosis.  
PCR was used targeting virulence genes and serotypes associated with invasive disease. 
Phylogenetic relatedness was determined with MLST. By analyzing DNA-sequences in 7 
different housekeeping genes, the method can separate isolates into distinct STs; isolates with 
identical allelic profiles, and into clonal complexes, here defined as groups of isolates sharing 
six loci of their allelic profiles with at least one other member of the group. The method is 
less discriminatory than pulsed-field gel electrophoresis due to the high evolutionary stability 
in the housekeeping genes, but is useful due to its internationally standardized system and the 
possibility of interlaboratory comparison.  [58, 59]. By using a computerized calculation tool 
Neighbor-joining trees could be drawn from MLST data and the relatedness is presented 
graphically in Fig.6. 
 
Figure 6A. Phylogenetic representation of isolates. Phylogenetic group KpI (n=96): blue, 
KpII (n=9): green and KpIII: red (n=34). From paper II. 
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Figure 6B. Minimal Spanning Tree (MST) based on MLST allelic profiles. The area of each 
circle corresponds to numbers of isolates. Black lines connect pairs of STs differing in one 
allele (thick line), two or three alleles (thin line) or four to seven alleles (dashed). Grey zones 
indicate a clonal complex. CC347, CC268, CC17 and CC253 were the most common clonal 
complexes (paper II). 
Most isolates belonged to phylogroup KpI (n=96), K. pneumoniae, followed by KpIII (n=34), 
K. variicola, and KpII (n=9), K. quasipneumoniae (Fig. 6). Hence the proportion of K. 
variicola was 24% in the study, relatively more common than reported in other studies [81, 
99]. There was a high diversity among the isolates. 116 different STs were found, and the 
majority did not belong to any clonal complex (Fig. 6B).  
Patients’ characteristics showed no differences between the phylogroups. Mortality within 30 
days was significantly higher among patients with BSI caused by K. variicola compared to K. 
pneumoniae , 29,4% versus 13,5% respectively (p=0.004, OR 3.0 (95% CI 1.1-8.4) adjusting 
for age and Charlson comorbidity index). One limitation was the small number of events (in 
total 24 out of 139 patients). 
Few isolates contained any of the serotypes associated with invasive disease or harbored VFs. 
Presence of VFs did not differ between patients with a fatal or non-fatal outcome. Over all 
there were low levels of antibiotic resistance. Resistance to one or several classes of 
antibiotics used in treatment for gram-negative infections, was 19% in K. pneumoniae 
compared to 6% in K. variicola (p=0.08). Previous studies support higher rates of 
antimicrobial resistance in K. pneumoniae isolates compared to K. variicola [81, 99]. Five 
ESBL-producers were found, all belonged to phylogroup KpI, K, pneumoniae. This was too 
few isolates to draw any strong conclusion, but it was in accordance with a study by Valverde 
et al. determining phylogenetic structure of ESBL-producing K. pneumoniae where most 
isolates belonged to KpI [100]. Thus, none of the investigated strain factors could explain the 
higher mortality among patients infected with K. variicola. To determine the frequency of K. 
variicola in laboratories is still complicated on an everyday basis, since distinction is most 
often made with molecular methods. Hence K. variicola remains underreported and instead 
reported as K. pneumoniae. The poorer prognosis when infected by K. variicola (II) has not 
yet been confirmed by other and larger studies. 
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4 ENTEROBACTERIACEAE AND ANTIMICROBIAL 
RESISTANCE 
“It is not difficult to make microbes resistant to penicillin in the laboratory by exposing them 
to concentrations not sufficient to kill them, and the same thing has occasionally happened in 
the body. The time may come when penicillin can be bought by anyone in the shops. Then 
there is the danger that the ignorant man may easily underdose himself and by exposing his 
microbes to non-lethal quantities of the drug make them resistant.” 
The discovery of penicillin by Alexander Fleming, first described in a publication in the late 
1920s [101], later in the 1940s leading to production of penicillin G, was revolutionary. 
Highly mortal diseases as pneumococcal pneumonia and war-associated wounds were now 
possible to cure. Fleming was awarded with the Nobel Prize in 1945 for his discovery. 
Already in his speech (above) he warned about microbes developing antimicrobial resistance. 
Years of consumption and overuse of antibiotics, both among humans, in animal production 
and agriculture, have now led to a situation threatening modern health care. 
Antimicrobial resistance (AMR), the ability of micro-organisms (bacteria, viruses, fungi and 
parasites) to withstand antimicrobial treatment, is considered by the World Health 
Organization (WHO) as one of the major human threats (www.who.int/drugresistance/en/). 
Fig.7 display the estimated annually deaths in 2050 attributable to AMR [102] according to 
the United Kingdom review on antimicrobial resistance 2014.    
 
 
 
Figure 7. Estimated number of annual deaths in year 2050 attributable to AMR (per 
continent) if development continues as now. From Review on Antimicrobial Resistance. 
Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations, 2014. 
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Already to this date thousands of persons annually die from complications due to AMR. 
Increasing resistance not only jeopardizes treatment against infections caused by MDR, but 
also situations where effective antibiotics are required, such as surgical procedures, advanced 
cancer treatment and the care of neonates [103]. 
Plasmids serve as vectors for transmission of resistance genes, and facilitate the 
dissemination of ESBLs. They acquire mobile genetic elements such as insertion sequences 
and transposons that mobilize the antimicrobial resistance genes. Plasmids are circular DNA 
molecules that replicate independently of the bacterial chromosome. A plasmid can contain 
between one and several hundred of genes encoding proteins for their own transfer, and also 
for bacterial virulence, antibiotic resistance and metabolic functions. They are not essential 
for bacterial survival, but can be advantageous for the bacteria. As plasmids often contain 
genes encoding for resistance to several antibiotic classes, multiresistance is common among 
EPE. The most frequent antimicrobial groups showing co-resistance to EPE include the 
fluoroquinolones, aminoglycosides and trimethoprim-sulfamethoxazole [104, 105]. Replicons 
control the plasmid replication. The classification in incompatibility groups (Inc) is based on 
the principle that plasmids sharing the same replicon cannot be propagated stably in the same 
cell. IncFII, IncN and IncI are examples of plasmids often harboring genes conferring 
resistance in Enterobacteriaceae [106]. Replicon typing was not performed within this thesis.  
4.1 PLASMID-MEDIATED Β-LACTAM RESISTANCE 
4.1.1 ESBL-producing Enterobacteriaceae – molecular features and 
dissemination 
After the first description of ESBLs in Germany in 1983 [107], a large number of plasmid-
mediated β-lactamases has been detected. Several different schemes have been used for the 
classification of β-lactamases. The classification proposed by Giske et al. in 2009 [108] is the 
most frequently used in Sweden and Norway (table 2). 
Table 2. Classification of ESBL enzymes and areas of endemicity 
Class of 
ESBL 
Ambler 
class 
Enzymes Phenotypic test 
Areas of endemicity 
[109-111] 
ESBLA A 
CTX-M, 
TEM/SHV-ESBL 
Inhibited by 
clavulanic acid 
Worldwide 
ESBLM C 
Plasmid-AmpC, 
mostly CMY 
Inhibited by 
cloxacillin 
ESBLCARBA 
A KPC 
Synergy with 
boronic acid 
Greece, Italy, Israel, 
Northern America, China  
B 
 
NDM, IMP Synergy with 
EDTA 
Indian subcontinent, the 
Balkans, the Middle East 
VIM Greece 
D OXA-48 
None available, 
temocillin R 
Northern Africa, the 
Middle East 
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In initial reports the TEM- (Temoneira) and SHV- (Sulfhydryl variable) enzymes dominated, 
mainly in K. pneumoniae. The number of TEM and SHV variants is now more than 220 and 
190 respectively (www.lahey.org/Studies/). CTX-M- (Cefotaximase-) enzymes were rare 
until the end of the 1980s. The CTX-M β-lactamases now exceed 170 different types 
(www.lahey.org/Studies/), and can be divided into five groups based on their amino acid 
identities: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25. CTX-M-15 belongs 
to the CTX-M-1 group, and is the most common enzyme both globally and in Sweden [112] 
At first most dissemination was associated with K. pneumoniae, but with the CTX-M-
enzymes, ESBL-producing enzymes were more commonly introduced in E. coli. This 
promoted rapid dissemination in the community and also made the EPE become an 
increasing problem in common community-acquired infections such as UTIs [104]. 
In 2007, the year that mandatory laboratory reporting of EPE was introduced in Sweden, 
almost 2100 new EPE-cases were detected. Since then the rate has increased every year, with 
over 9500 new cases during 2015 [113]. 
4.1.1.1 Resistance in the Stockholm area versus Europe 
The European Antimicrobial Resistance Surveillance Network (EARS-Net) is an 
international network that collects clinical antibiotic susceptibility data from all 28 European 
Union (EU) member states and two European Economic Area (EEA) countries, Iceland and 
Norway. The network is coordinated by the European Centre for Disease Prevention and 
Control (ECDC).  
To compare resistance rates in the K. pneumoniae and E. coli cohort from Karolinska 
University Hospital with data from European countries, data on invasive K. pneumoniae and 
E. coli isolates non-susceptible to third generation-cephalosporins were extracted from the 
ECDC database for the period 2006-2012 (paper III). To avoid sampling bias, countries 
reporting few isolates (a median of <300 E. coli isolates per year) were excluded, leaving 20 
countries, including Sweden. Data from EARS-net were population-weighted due to adjust 
for imbalances in reporting propensity and population coverage.  
The E. coli population among invasive infections at Karolinska University Hospital shows an 
increase of non-susceptibility to third generation cephalosporins during 2006-2012, from five 
to almost 13%, and the rate is comparable with the mean situation among the 20 included 
EARS-Net countries. In contrast, the K. pneumoniae population in the Stockholm area shows 
stable low rates of non-susceptibility between zero and five percent. This differs from the 
EARS-Net countries where more than 25% of the isolates were non-susceptible in 2012 (Fig 
8, from paper III). The few countries reporting higher third-generation cephalosporin non-
susceptibility in E. coli compared to K. pneumoniae all had generally low resistance 
frequencies, just as the cohort from Karolinska University Hospital [114]. The K. 
pneumoniae / E. coli (KP/EC) ratio was stable in the cohort from Karolinska University 
Hospital, while the KP/EC-ratio increased significantly (trend test p<0.001) over time in the 
EARS-Net data (Fig 8). 
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A. Karolinska University Hospital 
 
       
 
B.  EU/EEA, 20 countries reporting to EARS-Net. Population-weighted data 
 
       
KP/EC ratio  
E. coli non-susceptible to third-generation cephalosporins 
K. pneumoniae non-susceptible to third-generation cephalosporins 
 
Figure 8. Rates of invasive isolates non-susceptible to third generation cephalosporins 
among K. pneumoniae and E. coli 2006-2012, and KP/EC-ratio 
One explanation could be that there are no circulating MDR “high-risk clones” of K. 
pneumoniae in the Stockholm area. The isolates causing invasive infections between 2007 
and 2009 (paper II) showed a high diversity and internationally disseminating successful 
clones, such as CC258, could not be detected. The data in Fig. 8 support the absence of high-
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risk clones in the Stockholm area until 2012, as these would be expected to clonally expand 
and confer higher levels of resistance. 
4.1.1.2 Factors important for transmission of resistance 
Dissemination of EPE within a country and worldwide is multifactorial and includes humans, 
animals and environmental factors. Dissemination between household contacts has been 
shown in several studies [115, 116]. In a Norwegian study on infants colonized by EPE 
during an outbreak at the neonatal intensive care unit, transmission within households was 
observed in 9/28, 32% [32]. EPE has been detected as well in pets [117, 118], poultry and 
cattle [119] as in wild animals, for example birds [120]. In countries with high prevalence of 
intestinal EPE-colonization, dissemination occurs easily in the community. Except for the 
intestine in mammals and birds, several other reservoirs for EPE exist, for example sewage 
water and the surface of fruits and vegetables [121, 122]. ESBLs and the carbapenemase gene 
New Delhi metallo--lactamase (NDM-1) has even been reported in drinking water from 
New Delhi [123]. 
Prevalence of asymptomatic EPE carriership varies within different regions of the world. In 
Sweden the reported prevalence was 4.8% for samples collected 2012-2013 [6]. In Thailand a 
prevalence as high as 65.7% was reported from rural areas [124]. The carriership was 19% in 
a tribal area in India in a study from 2015 [125], while surveillance rectal swabs in 
outpatients presenting to pediatric oncology unit revealed high EPE carriership, 58.4%, with a 
rate of  CPE carriers of 20.2% [126]. Altogether resistance rates over 50% against extended-
spectrum cephalosporins have now been described in all WHO regions, albeit with 
considerable variation within the regions [127]. 
International travel has been associated with high frequency of EPE acquisition in several 
prospective studies. Traveling to southern Asia, including India, poses a particularly high 
risk. Diarrhea and use of antibiotics during the trip have been considered independent risk 
factors for acquisition. [29, 31, 128-132]. Paper IV is a prospective study on 188 Swedish 
travelers to four geographic areas with an expected high prevalence of EPE; Southeast Asia, 
the Indian subcontinent, Northern Africa and the Middle East (all travelers to this region went 
to Turkey). The study aimed to investigate the molecular features of EPE colonizing the gut 
after travel, and to determine risk factors for colonization. The travelers submitted one fecal 
sample before the trip and one upon return, and answered two questionnaires. EPE strains 
were characterized with molecular methods. 
Our results support previous findings with in total 56 out of 175 (32%) pre-travel negative 
participants colonized with EPE upon return. Colonization rates varied with visited 
geographic region, highest after traveling to the Indian subcontinent (49%) and northern 
Africa (44%), followed by Southeast Asia (19%) and Turkey (10%). In accordance with 
previous studies antibiotic treatment and diarrhea during the trip were independent risk 
factors for colonization (OR 5.92 (IV), table 3. [29, 128, 129, 131, 133].  
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Table 3. Risk factors for intestinal acquisition of EPE during travel. Multivariable analysis 
(paper IV). 
Characteristic Odds ratio (95% CI)  
Male sex 2.11 (0.96-4.65) 
Age 1.00 (0.98-1.03) 
Travel destination  
    Southeast Asia N/A 
    Indian subcontinent
 a)
 5.62 (2.27-13.89) 
    Northern Africa
 a)
 5.50 (1.78-16.94) 
    Turkey 0.81 (0.15-4.32) 
Travelers’ diarrhea 2.50 (1.04-6.03) 
Antibiotics during trip 5.92 (1.27-27.20) 
Chronic disease 0.27 (0.10-0.76) 
Bold face = P≤0.05 
 
a)
In relation to Southeast Asia 
 
 
The distribution of β-lactamases in relation to geographic region is displayed in Fig. 9 (IV). 
The enzyme distribution correspond to other studies on EPE in these regions with domination 
of CTX-M-1, and CTX-M-9 being frequently reported in Thailand [124, 132, 134]. CTX-M-
9 has only rarely been described in India [135], but was aqcuired by two persons after 
traveling here (IV). The majority of strains were E. coli (n=65), the two remaining were K. 
pneumoniae (n=1)  and Citerobacter freundii (n=1). 
 
 
 
Figure 9. Geographic distribution of ESBL-producing enzymes and total number of strains. 
Circle sizes correspond to acquisition rate (from paper IV). 
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Bacterial characteristics of the ESBL-producing E. coli found in the travelers study are 
displayed in table 4. Strains of phylogroup B2 and D more often showed multidrug-resistance 
(MDR) than strains belonging to phylogroup A and B1.This is in contrast to other studies 
reporting higher resistance rates among non-B2-strains [57, 136]. However, these studies 
included not only ESBL-producing isolates. The dominating resistance gene conferring 
ESBL in clinical isolates detected in Sweden is blaCTX-M-15, frequently carried by ST131 of 
phylogroup B2, known for epidemic dissemination and MDR. The distribution of 
phylogroups between the geografical regions differed – no B2-strains were detected in 
travelers to Northern Africa or Turkey. However, the small total number (n=8) needs to be 
considered. 
Table 4. Bacterial characteristics of ESBL-producing E. coli in relation to phylogroup. 
Modified from paper IV. 
 
 
 
Phylogroup 
A (n=28) 
Phylogroup 
B1 (n=12) 
Phylogroup 
B2 (n=8) 
Phylogroup 
D (n=17) 
MDR E. coli (n=32) 10 (36.0) 4 (33.3) 7 (87.5) 11 (64.7) 
Several (3 or more) VFs (n=5) 0 (0.0) 0 (0.0) 4 (50.0) 1 (5.9) 
Destination      
Southeast Asia (n=15) 7 (25.0) 2 (16.7) 2 (25.0) 4 (23.5) 
Indian subcontinent (n=36) 10 (35.7) 10 (83.3) 6 (75.0) 10 (58.8) 
Northern Africa (n=12) 9 (32.1) 0 (0.0) 0 (0.0) 3 (17.6) 
Turkey (n=2) 2 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) 
 
4.1.1.3 Duration of intestinal EPE colonization 
Duration of intestinal EPE colonization is individual and affected by both environmental- and 
host factors. Difficulties in detection of low bacterial numbers in a fecal sample makes data 
on elimination uncertain, as re-detection of the original strain can occur after several negative 
samples [137]. One study following colonization among newborns and their parents showed 
longer persistence among infants (median 12.5 months) than among parents (median 2.5 
months) [32]. Colonization seems to persist longer after a clinical infection caused by EPE 
than among healthy gut-colonized individuals showing no symptoms of clinical infection. 
Persistence of carriership has been seen in up to 44% one year after infection. [30, 32]  Only a 
limited amount of studies have followed asymptomatic EPE carriers. A recent French study 
from Ruppé et al [31] investigated the RA of multidrug-resistant Enterobacteriaceae in 
travelers to tropical regions, and followed the persistence of colonization. The overall 
acquisition rate was 51% upon return, but only 4.7% remained carriers after three months. 
Carriage lasted longer in travelers returning from Asia and in travelers with a high RA on 
return. In our study (IV) we did not evaluate duration of carriership. However we found that 
among 13 travelers with EPE colonization before traveling, EPE was found in only six 
travelers upon return. Identification of strains with repetitive sequence-based PCR (rep-PCR, 
DiversiLab) revealed that only four of the initial strains were recovered upon return, all of 
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them belonged to phylogroup B2. This phylogroup has also previously been connected with 
prolonged carriership [30]. The CTX-M-1 producing strain ST 131 belongs to this 
phylogroup, and its adaptation as a commensal as well as a pathogen is well known [23]. In 
paper IV 65 out of 67 EPE strains among the travelers were E. coli. Phylogrouping revealed 
that most strains (57/65, 88%)  were non-B2, and that the non-B2 strains carried few VFs. 
Possibly this could indicate both low risk of future clinical infection and shorter colonization 
time during these asymptomatic travelers. No clinical infections were observed during 10-26 
months of follow-up (IV). To my knowledge no studies evaluating RA in relation to bacterial 
characteristics has been performed, but it would be of interest to study if phylogroup B2 is 
connected to high RA. 
4.2 CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE 
1993 was the first time carbapenemase production was detected in Enterobacteriaceae. It was 
in a clinical isolate of Enterobacter cloacae, a chromosomally encoded NmcA [138]. Since 
then a large variety of plasmid-mediated CPEs have been identified. The carbapenemases 
belong to the Ambler class A, B and D, and the main ones are listed in table 2. 
4.3 CPE IN SWEDEN 
Although still rare among clinical infections in Sweden, carbapenemase-production among 
Enterobacteriaceae is rapidly increasing. In 2012, in addition to mandatory laboratory 
reporting, ESBLCARBA also became mandatory for clinicians to report. In 2015 there were 
totally 115 new reports of ESBLCARBA, 43 of which from the Stockholm area (Fig. 10). Most 
cases were found in fecal screening samples. Only 24 out of the 94 cases in Sweden between 
2007 and 2012 were isolates from clinical infections [139]. Most cases had recently had a 
health care contact in an endemic country. As in previous years, the proportion of the isolates 
acquired abroad during 2015 was almost 80%. During the last months of 2015 there was an 
increase in reports. Syria (n=19), followed by Turkey (n=11), India (n=7) and Greece (n=5) 
were the most frequently reported countries in 2015 [140].  
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Figure 10. Number of cases of carbapenemase-producing Enterobacteriaceae in Sweden and 
type of enzyme, 2007-2015 (SWEDRES 2014, 2015 www.folkhalsomyndigheten.se, 
unpublished data). Due to some cases harboring several resistance genes, the figure does not 
display the exact number but the proportion within each enzyme group. 
4.3.1.1 Global dissemination of CPE 
KPC enzymes were first detected in a K. pneumoniae isolate in the United States in 1996, 
showing resistance to all β-lactams. In the early 2000s epidemic outbreaks of CPE were 
reported from Greece, the USA, and later from Israel. KPC is now endemic in Greece, and 
the most common carbapenemase among Enterobacteriaceae in Europe, but have also 
disseminated in South America and China. [109, 141]. In data from EARS-net 62% of 
invasive K. pneumoniae isolates reported from Greece in 2014 were non-susceptible to 
carbapenems. In Italy, an outbreak of KPC among K. pneumoniae resulted in an increase of 
carbapenem resistance in invasive K. pneumoniae from one to 27 % between 2009 and 2011. 
In 2014 the rate had increased further up to 33 % (http://ecdc.europa.eu).  KPC is most 
common in K. pneumoniae but can also be expressed by other Enterobacteriaceae as well as 
by Pseudomonas aeruginosa. KPC is associated with the worldwide disseminated ST258 
[80]. 
The metallo-β-lactamases include IMP, VIM (Verona integron-encoded metallo-β-
lactamase), and NDM (New Delhi metallo-β-lactamases) enzymes. IMP was first recognized 
in Japan in the end of the 1980s in Pseudomonas aeruginosa [142]. A VIM-positive isolate 
was first observed in P. aeruginosa  in Verona, Italy, in late 1997 [143], and later 
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disseminated to other Enterobacteriaceae, especially K. pneumoniae. VIM is still common in 
Greece, but has been reported also from many other parts of the world [144].NDM-1 was 
described for the first time in 2010 [145], originating from the Indian subcontinent. NDMs 
are highly prevalent on the Indian subcontinent and in the Middle East with prevalence rates 
of NDM-producers among Enterobacteriaceae ranging from 5 to 18.5% in Indian and 
Pakistani hospitals. It has also been detected in drinking water and seepage samples in New 
Delhi [123]. NDM has been imported into European countries on several occasions, mainly 
detected in hospitalized patients transferred from endemic areas. As NDM is being reported 
not only in K. pneumoniae, but also in E coli they entail a high risk both for dissemination in 
the community, and to cause community-acquired infections. NDMs are also seen in 
Acinetobacter spp and, more rarely, in P. aeruginosa [146, 147]. 
Oxacillinase-type -lactamase (OXA-48) enzyme was for the first time identified in a 
carbapenem-resistant K. pneumoniae in Turkey in 2001 [148]. After that OXA-48-like 
enzymes have emerged and disseminated in mainly Northern Africa and the Middle East, but 
also caused outbreaks in several European countries such as the UK, France, Germany, 
Belgium and the Netherlands [149]. They are still mostly detected among K. pneumoniae, but 
have also been reported in other species. Strains containing OXA-48-like enzymes often 
express only discrete elevation of carbapenem minimal inhibitory concentration (MIC) [149], 
challenging detection. 
 
 
 
Figure 11A. Invasive E.coli isolates with non-susceptibility (intermediate or resistant) to 
carbapenems, EU/EEA countries, 2014, percentage. (EARS-Net database 2014) 
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Figure 11B. Invasive K. pneumoniae isolates with non-susceptibility (intermediate or 
resistant) to carbapenems, EU/EEA countries, 2014, percentage. (EARS-Net database 2014). 
Carbapenemase production is so far more common in K. pneumoniae than in E. coli isolates 
in most European countries (Fig. 11) as well as in other geographical regions. Although high 
rates of CPE are reported from the regions visited in paper IV [150], none of the travelers 
aqcuired CPE. To this date there are only few reports of healthy travelers acquiring 
carbapenemase-producers [151] . One possible explanation is that CPE still is more common 
among K. pneumoniae compared to E. coli, which is the bacteria most commonly aqcuired in 
the community. If carbapenem resistance rates increases in the E. coli population in the 
future, the dissemination in the community will probably speed up. Lack of effective 
therapies against common community-acquired infections caused by E. coli will also increase 
with such scenario. 
4.4 PLASMID-MEDIATED NON Β-LACTAM RESISTANCE 
Plasmid-medicated co-resistance to other antibiotic groups often occurs in EPE. Some of the 
clinically most important are presented below. The modes of transmission of resistance genes 
between bacterial strains are similar to those of β-lactam resistance. 
4.4.1 Plasmid-mediated aminoglycoside resistance 
The most common mechanism is production of aminoglycoside modifying enzymes (AMEs). 
Several AMEs exist, the most common plasmid-mediated in Enterobacteriaceae is 
aminoglycoside acetyl-transferase, encoded by Aac(6´). Expression of Aac(6´) can confer 
resistance both to amikacin and gentamicin, although not compulsory [152]. No isolates in 
our study harbored Aac(6´)-Ib, but 10 strains harbored Aac(6´)-Ib-cr, encoding a variant of 
aminoglycoside acetyl-transferase capable of inactivating aminoglycosides as well as 
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reducing ciprofloxacin activity. Only two out of these 10 isolates showed non-susceptibility 
against amikacin, while five were resistant against gentamicin (IV). The plasmid-mediated 
16S rRNA methylase provides high-level resistance to aminoglycoside antibiotics including 
not only gentamicin, but also amikacin and tobramycin. There are several 16S methylase 
genes, including armA, rmtA, rmtB, rmtC and rmtD [153]. The two isolates in our study (IV) 
resistant both to amikacin and gentamycin harbored rmtB. 
4.4.2 Plasmid-mediated quinolone resistance 
In 1998 qnrA, a plasmid-mediated quinolone resistance gene, was found for the first time in a 
urine specimen of a K. pneumoniae isolate [154].Up to now, three plasmid-mediated 
mechanisms of quinolone resistance have been described. The Qnr gene group encodes 
proteins that bind to DNA-gyrase or to topoisomerase IV inhibiting the mechanisms of 
quinolones. Aac(6´)-Ib-cr encoded aminoglycoside acetyl-transferase can reduce 
ciprofloxacin activity through acetylation, as well as inactivate aminoglycosides. QepA and 
QqxAB are plasmid- mediated genes upreglating efflux pumps. All of the 10 isolates 
harboring aac (6’)-Ib-cr in our study (IV) were non-susceptible to ciprofloxacin. Only 10 out 
of 24 qnr-positive isolates were non-susceptible to ciprofloxacin, 2 of these strains also 
harbored aac (6’)-Ib-cr. Thus presence of qnr does not always confer clinical resistance, 
which has also been shown previously [155]. 
4.4.3 Plasmid-mediated colistin resistance 
Chromosomally mediated colistin resistance has been reported both in EPE and non EPE. In 
November 2015, a plasmid-mediated colistin resistance gene, mcr-1, was described in a 
Chinese study [156]. Expression of mcr-1 contributes to modification of lipid A, resulting in 
reduced polymyxin affinity. The gene was detected in E. coli isolates both from animals, food 
and patients. Only a month after the first report, Hasman et al also reported a mcr-1 positive 
E. coli isolate coproducing also CTX-M-55 and an AmpC (CMY-2). This isolate was 
detected in blood in a patient in Denmark. Mcr-1 was also found in EPE from imported 
chicken meat [157]. Although recently detected, the mcr-1 gene has been present for a long 
time. Positive isolates dating back to the 1980s have been found from chicken in China. The 
prevalence of mcr-1 is still uncertain since most studies have only investigated mcr-1 in 
colistin resistant isolates [158]. We reported the first case of mcr-1 expression in Sweden 
(IV) from a traveler after a trip to Thailand. The traveler reported neither gastrointestinal 
symptoms nor antibiotic intake during the trip or on return. As the trip took place during late 
2013, more cases of mcr-1 gut colonization among Swedes most probably exist. Within the 
Public Health Agency’s surveillance program for enterohaemorragic E. coli (EHEC), another 
E. coli strain harboring mcr-1 have been detected in an asymptomatic Swede after traveling in 
Asia [159]. The future impact of mcr-1 is too early to predict, but the gene is capable of 
transfer into rapidly disseminating epidemic EPE producing strains such as E. coli ST131. It 
has also recently been detected in a KPC-producer isolated from an infected wound [160]. 
The clinical consequences of dissemination of CPE harboring mcr-1 could be devastating due 
to the risk of total lack of effective antibiotic treatment against such infections.  
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5 DETECTION OF CPE 
Detection of CPE is complicated as paradoxically some CPE show only low levels of 
carbapenem resistance. Carbapenem resistance in Enterobacteriaceae can also be caused by 
other mechanisms than production of carbapenemases. Isolates producing ESBLA and AmpC 
can confer also carbapenem resistance when combined with chromosomal porin mutations 
that prevent influx of β-lactam antibiotics in the bacteria; they are not classified as 
carbapenemases. Reduced permeability is most often associated with higher cost of fitness 
than carbapenemase-production, hence EPE resistant also to carbapenems due to loss of 
porins can be challenging in a therapeutic way but poses less risk of further dissemination. 
Increased expression of efflux systems in bacteria under antibiotic pressure can also 
contribute to resistance, also a mechanism separated from carbapenemase production. 
5.1 ANTIMICROBIAL SUSCEPTIBILITY TESTING 
The goal of antimicrobial susceptibility testing is to predict the in vivo success or failure of 
antibiotic therapy. Either the minimal inhibitory concentration (MIC-value, mg/L), or zone 
size (mm) is measured. Bacterial susceptibility for a certain antibiotic is defined as: 
S= susceptible. Isolates are inhibited by the achievable concentration of the antimicrobial 
agent when adequately dosed, clinical efficacy is likely. 
I = intermediate. Uncertain effect of the certain antibiotic, response rates may be lower than 
for susceptible isolates and possibly low-grade resistance against the antibiotic. Clinical 
efficacy in body sites where the antimicrobials are physiologically concentrated or if the drug 
is given in higher dosage. 
R= resistant. Isolates are not inhibited by the antimicrobial agent in achievable 
concentrations, clinical efficacy is unlikely. 
The MIC for a species varies depending on resistance mechanisms, but also within bacterial 
populations lacking resistance mechanisms against the specific antibiotic, the wild type (WT). 
The epidemiological cutoff values (ECOFFs) represent in most cases the upper MIC values 
of the WT distribution [161].  
The MIC breakpoints are both used to predict clinical success in antimicrobial treatment 
against bacterial infections and for surveillance of antimicrobial resistance. When 
determining the MIC breakpoints several variables are taken into account – e.g. 
pharmacokinetics, pharmacodynamics, dosages, resistance mechanisms, MIC- and zone 
diameter distributions and ECOFFs [161]. 
5.1.1 Determination of the MIC-value 
Different methods used to determine antibiotic susceptibility are presented in Fig. 12. Broth 
microdilution is the reference method according to the ISO standard 20776-1 (2006). A tray 
containing several wells is prepared with antibiotics diluted in broth in different 
concentrations before adding samples. After incubation MICs are determined by using 
manual or automated viewing device for inspection of each well. The MIC is similar to the 
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lowest antibiotic concentration where no bacterial growth is seen. In the gradient test, a strip 
containing antibiotic in a gradient concentration, is applied on inoculated plates. After 
incubation the MIC value is determined. Disk diffusion is widely used at the microbiological 
laboratories. Antibiotic discs are placed on plates inoculated with bacteria. After incubation 
the inhibiting zone is measured in mm. This method does not determine the actual MIC but 
small zones correspond to high a MIC-value, and it thus serves as a surrogate method [162]. 
        
 
 
Figure 12. Antimicrobial susceptibility testing using 
gradient test, disk diffusion and broth microdilution for 
a strain susceptible only to meropenem. 
A. The MIC-value is interpreted where the 
bacterial growth is inhibited, here at a value of 
0.5 mg/L.  
B. Higher antibiotic concentration close to the 
antibiotic disks inhibit bacterial growth and 
the inhibited bacterial zone (dark blue) 
diameter is measured in mm. 
C. Broth microdilution showing bacterial growth 
(yellow), the lowest antibiotic concentration in 
a well showing non-growth (dark blue) is the 
MIC-value. 
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Different Automated Susceptibility Testing systems (ASTs) have been developed the last 
years. VITEK2 (bioMérieux), Phoenix, and MicroScan (Siemens) are systems using panels 
prepared with antibiotics in different gradients. With automated software results can be 
obtained within a few hours [162]. 
5.1.2 Challenges in detection of CPE 
Rapid detection of carbapenem-resistance in Enterobacteriaceae is of importance. Most 
empiric antibiotic treatment against severe infections suspected to be caused by gram-
negative bacteria, include the use of β-lactams. Since most CPE-isolates are highly resistant 
to β-lactams including carbapenems, empiric antibiotic therapy is often delayed. Early 
adequate treatment is crucial for prognosis in severe infections [163].  
For epidemiological reasons, and to guide infection control interventions preventing further 
dissemination, reliable detection of carbapenemases is of major importance. When initializing 
the first project included in this thesis, it was known that CPE can express carbapenem 
resistance in different degrees, ranging from resistant to susceptible using the European 
Committee of Antimicrobial Susceptibility Testing (EUCAST) and the Clinical Laboratory 
Standards Institute (CLSI) clinical breakpoints. As carbapenemase expression vary, 
breakpoints used for treatment of clinical infections were not adequate to use in 
epidemiological screening. In order to find breakpoints for epidemiological screening we 
studied 51 isolates of K. pneumoniae with a known production of either KPC (n=31) or VIM 
(n=20) in paper I. At the time of the study KPC and VIM were the clinically most important 
carbapenemases. Antibiotic susceptibility testing was performed with disk diffusion, gradient 
test (Etest) and automated susceptibility testing (VITEK2) against the carbapenems 
imipenem, meropenem and ertapenem. The results were interpreted with the, at that time 
used, clinical EUCAST and CLSI breakpoints for carbapenems as well as EUCASTs ECOFF 
values (Fig. 13).  
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Figure 13. Susceptibility testing using disk diffusion and gradient test for the carbapenems 
imipenem, meropenem and ertapenem. The dashed black lines indicate the ECOFF (WT), 
EUCAST, and CLSIs clinical breakpoints before 2011 (paper I). The dashed blue lines 
indicate the current EUCAST screening cut-off. 
As seen in Fig. 13, the clinical breakpoints used at the time the study was performed are not 
suitable for epidemiological screening. Meropenem was the best suited carbapenem to use for 
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screening purposes. A breakpoint of 0.5 mg/L found all isolates with an at the same time 
good separation from the WT. 
After this study was performed another carbapenemase genotype, OXA-48, has emerged. 
Strains containing OXA-48-like enzymes often express only discrete elevation of carbapenem 
MICs [149]. Carbapenemase-production has also been introduced in E. coli, where MICs 
usually are below the clinical cut-off values [164]. The diversity of enzymes conferring 
carbapenemase-resistance in different species has made detection even more challenging. 
Previous studies show that ertapenem has high sensitivity but poor specificity, due to 
impermeability caused by loss of porins, and simultaneous β-lactamase production other than 
carbapenemases [165-167]. As seen in Fig. 13 imipenem shows a poor separation between 
the WT and the cut-off value. The best performing carbapenem used in screening is therefore 
meropenem.  
CLSI published new (lowered) MIC breakpoints in January 2011 to capture mainly KPC-
producers with the clinical breakpoints. EUCASTs breakpoints are not set for detection of 
carbapenemases but to be used as clinical breakpoints to predict treatment response. Due to 
the large span of MIC among CPE, EUCAST has defined a specific cut-off used for 
screening purposes (table 5). 
Table 5. CLSI and EUCAST current breakpoints for Enterobacteriaceae and carbapenems 
(http://em100.edaptivedocs.com, http://eucast.org/clinical_breakpoints/) 
 CLSI EUCAST ECOFF Screening 
cut-off 
(EUCAST) 
Gradient 
test (Etest)  
S 
MIC 
(mg/L) 
R 
MIC 
(mg/L) 
S  
MIC 
(mg/L) 
R 
MIC 
(mg/L) 
WT 
MIC 
(mg/L) 
 
mg/L 
Imipenem ≤1 ≥4 ≤2 >8 ≤0.5*≤1** >1 
Meropenem ≤1 ≥4 ≤2 >8 ≤.0.125 >0.125 
Ertapenem ≤0.5 ≥2 ≤0.5 >1 ≤0.064 >0.125 
Disk 
diffusion 
 
S 
Zone 
diameter 
(mm) 
R  
Zone 
diameter 
(mm) 
S  
Zone 
diameter 
(mm) 
R 
Zone 
diameter 
(mm) 
WT 
Zone 
diameter 
(mm) 
 
Imipenem ≥ 23 ≤ 19 ≥22 <16 ≥24*≥23** <23 
Meropenem ≥ 23 ≤ 19 ≥22 <16 ≥25 <25*** 
Ertapenem ≥ 23 ≤ 19 ≥25 <22 ≥29*≥25** <25 
 
*E. coli 
**K. pneumoniae 
***During outbreaks of OXA-48-producers elevated screening zone diameter can be proposed as OXA-48 in 
rare cases have zone diameters of 24-26 mm 
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Using VITEK2 four KPC-producers were not detected when using a card containing 
imipenem as the only carbapenem (AST N027) (I). Woodford et al. compared how well 
different commercial systems (BD Phoenix, Microscan and VITEK2) inferred the presence of 
a carbapenemase. Their study showed poor detection of OXA-48-producers but more reliable 
detection with KPC and metallo-carbapenemases [168]. Automated systems can be useful 
tools for CPE detection but results must be compared with the carbapenem MIC correlates, 
and appropriate phenotypic and/or genotypic methods should be used to exclude CPE if 
carbapenem MIC correlates are above the lower detection limit in the card. 
Determining the cut-off value for screening for CPE is a balance striving for high sensitivity 
in combination with highest possible specificity. However, since carbapenemases even with 
low carbapenem MICs are important to detect for infection control purposes, sensitivity is of 
greater importance than specificity. In a recent study [164] application of CLSI screening 
recommendations captured only 86% of CPE isolates, whereas using the EUCAST 
recommendations showed a high sensitivity, 98.4%. In our study (I) the EUCAST screening 
cut-of for meropenem would detect all isolates, while the current CLSI MIC breakpoints for 
meropenem would interpret 49 out of 51 (96%) of the isolates as non-susceptible (I or R). A 
high sensitivity, however, our study contained only KPC and VIM-producing K. pneumoniae 
isolates. 
5.2 PHENOTYPING AND GENOTYPING 
For detection of carbapenemases, phenotypic methods are applied on isolates with reduced 
susceptibility to carbapenems. As different enzymes conferring carbapenem-resistance show 
different phenotypes, EUCAST has proposed an algorithm for detection of carbapenemases 
as displayed in Fig. 13.  
 
 
*OXA-48, temocillin R 
 
Figure 13. Algorithm proposed by EUCAST for detection of CPE. 
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The presence of OXA-48-like enzymes is confirmed with genotypic methods as there are no 
available inhibitors at present. Isolates carrying OXA-48-like enzymes show high-level 
resistance to temocillin (MIC >32 mg/L), however temocillin has low specificity as other 
mechanism can confer resistance against the antibiotic [169]. To confirm genotype among 
CPE, most often PCR is performed targeting common enzymes.  
5.3 FUTURE DIAGNOSTICS 
Direct molecular detection of carbapenemases is appealing due to the time gain in detection. 
There are some commercial systems for direct molecular detection in feces available, most 
suitable for high-prevalence areas or during outbreaks [170-172]. One limitation of these 
methods is that they can only detect the genotypes included in the analysis for which reason 
novel or rare genotypes will remain undetected. 
Whole genome sequencing (WGS), the most comprehensive method for analyzing bacterial 
genomics, can be performed with different methods. Next-generation sequencing is a rapid 
method based on pyrosequencing. In the future WGS will most likely be more frequently 
used in routine diagnostic settings, for surveillance of antimicrobial resistance, contract 
tracing and analysis of outbreaks [173, 174]. The advantages of WGS (and publicly available 
sequence databases) are exemplified in the case of mcr-1, where knowledge has rapidly 
expanded within just a few months after the first description.  
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6 TREATMENT OF INVASIVE INFECTIONS CAUSED BY 
CPE 
Implications on antibiotic treatment of CPE were not included in this thesis, but will be 
described in short. Invasive infections caused by CPE are associated with high mortality, 
ranging from 20 to 70% [175] and the death attributable to carbapenem-resistance has been 
calculated to 26-44 % [5]. The lack of therapeutic options in infections caused by MDR 
Enterobacteriaceae has led to the reintroduction of old antibiotic agents. New antibiotic 
classes with novel mechanisms of action against gram-negative infections are not to be 
expected in the near future. Treatment regimens against CPE are debated and the literature 
consists mostly of small retrospective studies or case-reports, where either monotherapy or 
different combination therapies have been used. In summary most studies favor combination 
treatment always including a carbapenem if MIC≤ 4 (-8) mg/L plus at least one of the 
antibiotics listed below depending on susceptibility [176-179]. 
6.1 CARBAPENEMS 
The carbapenems (e.g. imipenem, meropenem, ertapenem and doripenem) are β-lactam 
antibiotics stable to ESBLA and –M. They possess the widest spectrum of antibacterial activity 
covering most gram-positive and gram-negative aerobic and anaerobic bacteria and play an 
important role in the treatment against severe infections caused by EPE. Reduced membrane 
permeability due to loss of porins and efflux pumps in combination with ESBL-production 
can however cause a carbapenem resistant phenotype. CPE hydrolyze also carbapenems, but 
not all CPE express high-level resistance. The use of a carbapenem in combination therapy 
against severe infections caused by CPE has shown improved outcome when carbapenem 
MIC-values are ≤ 4 and even up to 8 mg/L [176, 178].  
6.2 COLISTIN 
Colistin is a polypeptide antibiotic discovered in 1947, but rarely used until lately, primarily 
due to kidney toxicity. Now though, due to MDR, it has been revived as the drug of choice in 
treatment against infections caused by CPE. The target of action is the lipopolysaccharide, 
where destabilization of the outer membrane of gram-negative bacteria causes increased 
permeability and cell death. However, resistance rates are increasing in areas where the agent 
is extensively used. From Italy colistin resistance rates of >40% have been reported in KPC 
producers [180]. Used in monotherapy, high mortality rates of 50% are reported [177].  
Combination therapies with either meropenem, tigecycline or an aminoglycoside, or 
combination of several of these agents, have been more successful [178, 179]. 
6.3 FOSFOMYCIN 
Fosfomycin acts on bacterial cell wall synthesis, conferring bactericidal effect on a broad 
spectrum of gram-positive and gram-negative bacteria. It shows effect against most CPE-
producers. Resistance due to plasmid-mediated enzymatic modification of the antibiotic is 
now emerging, and resistance rates are increasing, especially in areas where the agent is 
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widely used. However, development of resistance in clinical studies appears lower than rates 
expected from in vitro data [181, 182]. Clinical studies on fosfomycin are scarce in invasive 
infections caused by CPE, but one study show effect when adding fosfomycin in severe CPE 
infections [183]. Fosfomycin can be both orally and intravenously administrated. Intravenous 
fosfomycin is presently not available in Sweden.  
6.4 TIGECYCLINE 
Tigecycline is a tetracycline derivative. Low renal excretion limits the usefulness in 
infections originating from the urinary tract. Despite the high susceptibility rates among 
ESBLs including carbapenemase-producing E. coli, tigecycline has limitations in the 
treatment of severe infections due to its bacteriostatic effect. Breakthrough bacteremia has 
been reported during treatment against VIM-producing K. pneumoniae susceptible to the 
agent, as well as increased mortality in clinical studies. Higher dosing regimens have been 
proposed as low serum concentrations occur with standard dosing. Tigecycline is not 
recommended as monotherapy unless other options are lacking [184, 185]. 
6.5 AMINOGLYCOSIDES 
Aminoglycosides are bactericidal agents, inhibiting bacterial protein synthesis. They are used 
for treatment of infections in the urinary tract, where the antibiotic concentration is high, but 
their efficacy in severe infections of other source than the urinary tract is more limited. Some 
CPE are susceptible to gentamycin, and a few to amikacin. In case of susceptibility an 
aminoglycoside can be used in combination therapy against infections caused by CPE [186, 
187]. 
6.6 NEW AGENTS 
New antibiotic classes acting against CPE are not to be expected in the near future. However, 
some new compounds within already existing classes are recently registered or under 
investigation in clinical trials. 
Plazmomicin is a semisynthetic derivate of sisomicin, an aminoglycoside with improved 
activity against amikacin- or gentamicin-resistant strains. It has shown high in vitro effect 
against CPE, however, strains harboring ArmA or RmtC 16S RNA methyltransferase (mainly 
NDM-producers) are resistant. A phase III trial is currently ongoing comparing the agent with 
colistin when combined with a second antibiotic (either meropenem or tigecycline) in the 
treatment of patients with BSI, hospital acquired bacterial pneumonia, or ventilator-
associated bacterial pneumonia due to CPE [188][186, 189].  
Avibactam is a β-lactamase-inhibitor that, in combination with ceftazidime, has been 
clinically available in the USA since February 2015. The indications are complicated intra-
abdominal infections (in combination with metronidazole), and complicated urinary tract 
infections (including pyelonephritis), with limited or no alternative treatment options. In vitro 
avibactam can inhibit the activity of Ambler class A, C and D, but not class B metallo-β-
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lactamases (NDM, VIM or IMP). Addition of avibactam to ceftazidime greatly reduces the 
MIC value for most Enterobacteriaceae isolates compared with ceftazidime alone [179, 190]. 
Eravacycline is a tetracycline derivate that inhibits protein synthesis. It shows activity against 
KPCs. Phase III studies comparing efficacy versus carbapenems in intraabdominal infections 
and versus levofloxacin in UTIs are ongoing [191].   
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7 FUTURE 
Antibiotics reduce mortality in severe infections. Efficient antibiotics are a prerequisite for 
modern health care. New antibiotic classes against gram-negative infections are not to be 
expected in the near future, why the currently available must be used in a rational way, 
considering the growing challenge from antibiotic resistance. 
Prescribing patterns vary worldwide and mirror the level of antimicrobial resistance. In 
Europe high-prescribing countries have higher prevalence of antimicrobial resistance and 
vice versa. Greece showed the highest prescription rates of antibiotics in the primary care 
sector during 2014, 34.0 daily delivered doses (DDD) per 1000 inhabitants and per day. This 
is more than three times as much as the lowest prescribing country, the Netherlands, with a 
prescription rate of 10.6 DDD per 1000 inhabitants and per day. In Sweden the rate was 13.0 
DDD per 1000 inhabitants and per day in 2014 (http://ecdc.europa.eu). Increased use of 
broad-spectrum antibiotics due to high prevalence of MDR doubtlessly leads to further 
selection of resistant strains. The regional differences in prescribing patterns are substantial 
even within Sweden, where Stockholm County has one of the country’s highest prescriptions 
rates of antibiotics. However, between 2009 and 2015 the number of prescriptions decreased 
with 18%, from 430 to 352 per year and 1000 inhabitants (Concise, e-health Authority, 
www.ehalsomyndigheten.se), still over-prescription can be further reduced. 
To limit the use of antibiotics therapeutic alternatives are sought in the treatment of 
uncomplicated infections. One example is in sporadic urinary tract infections, where 
antibiotics currently mainly are offered as symptomatic treatment in healthy individuals. A  
German study on 80 patients with cystitis showed no inferiority in relief of symptoms using 
ibuprofen compared to ciprofloxacin [192]. 
The intestine serves as a huge reservoir for resistant Enterobacteriaceae. Different attempts to 
affect the intestinal microbiota have been studied in order to eliminate colonization. Selective 
digestive or oral decontamination (SDD, SOD) - administration of topical and/or oral 
antibiotics - has been used in ICUs to prevent from invasive infections. A recent meta-
analysis supports its use [193]. Colistin and aminoglycosides are common components in 
SDD due to their gram-negative profile, their sparse effect on anaerobes, and their minimal 
systemic uptake when orally administered. However, several studies report increased colistin 
and aminoglycoside resistance during or after the use of SDD [194-196]. The recent finding 
of mcr-1 has again put focus to the question in order not to jeopardize possible treatment 
alternatives against multidrug-resistant gram-negative infections. In studies on decolonization 
of intestinal EPE carriers where SDD has shown effect, it has not been persistent [197, 198].  
Another approach is fecal transplantation, a treatment proven efficient against severe 
clostridial infections. Fecal microbiota transplantation is reconstitution of normal microbiota 
from a healthy donor [85, 199]. The mode of administration has prevented large-scale use 
why new packages are under development. In American pilot study 20 patients with recurrent 
diarrhea caused by C. difficile received capsulized frozen fecal microbiota. The cure rate was 
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70 and 95% with one and two treatment courses and no adverse events occurred [200]. 
Combining SDD and fecal transplantation is a theoretically interesting approach, but to my 
knowledge, no such study has yet been published. If SDD is to be used in order to eliminate 
EPE carriership, patients must be selected carefully, as the choice of antimicrobial agent. A 
carrier of a more pathogenic strain is probably at higher risk for a future infection caused by 
that strain than a carrier of a strain without factors of pathogenesis. However, as plasmids 
share genetic information both within the species to bacteria with other phylogenetic origin, 
and to other species, there is a great complexity. No studies evaluating RA and phylogenetic 
origin of EPE have, to my knowledge, yet been performed, but it would be of interest to see if 
there is a link, as it is easier to determine phylogroup than RA. 
Further studies on risk assessment of infections caused by EPE when colonized are needed in 
order to prevent the overuse of broad-spectrum antibiotics ”just in case”. Studies on how 
often a gram-negative BSI is caused by EPE versus non EPE when a patient is colonized with 
ESBL-producing bacteria could be one approach. 
Lastly, the recently discovered (but not new) plasmid-mediated colistin resistance gene mcr-1 
exemplifies the difficulties and challenges that are to be expected in the future in the combat 
against the explosive dissemination of antimicrobial resistance.  
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8 CONCLUSIONS 
Overall this thesis provides new insights in invasive infections related to K. pneumoniae and 
sister species, increased knowledge on detection of CPE and on molecular characteristics of 
EPE colonizing the intestine after travel. More specifically:   
 Meropenem is the most suitable carbapenem to use in epidemiological screening for 
KPC- and VIM-producing K. pneumoniae. 
 There are currently no signs of dissemination of high virulent K. pneumoniae clones 
in the Stockholm area.  
 K. variicola (K. pneumoniae phylogroup KpIII), is a frequent pathogen among 
invasive infections diagnosed as K. pneumoniae, and associated with higher mortality 
than phylogroup KpI (K. pneumoniae sensu stricto). 
 Invasive infection caused by K. pneumoniae affects patients with high comorbidity 
and mortality within 90 days is high due to patient factors. 
 The risk for intestinal acquisition of EPE is high when traveling to the Indian 
subcontinent and Northern Africa, and also of importance when traveling to Southeast 
Asia and Turkey. 
 The risk for acquisition of CPE is still low even when traveling to areas with an 
estimated high prevalence of CPE. 
 Traveler’s diarrhea and antimicrobial treatment are both independent risk factors for 
intestinal EPE acquisition. 
 Phylogroup A and B1, normally commensal strains, are in majority among gut-
acquired EPE during travel; strains host few virulence factors and are less co-resistant 
than clinical isolates. 
 Plasmid-mediated colistin resistance gene, mcr-1, has now been detected in Sweden, 
after acquisition in Thailand. 
 
Hopefully the studies in this thesis contribute to reliable detection of CPE, a deeper 
understanding of the molecular features of EPE as a gut colonizer, and new insights in K. 
variicola as a pathogen with substantial mortality in invasive infections. 
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